CinDome Pharma
Business Services · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5375 Medpace Way, Cincinnati, Ohio, 4522...Phone Number
(513) 579-9911Website
www.cindome.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CinDome Pharma
CinDome Pharma, a CinRx portfolio company, is focused on developing deudomperidone (CIN-102) for the treatment of chronic gastroparesis, a condition affecting millions in the U.S. The company aims to provide a safe and effective long-term therapy for patients suffering from this debilitating condition, which currently lacks adequate treatment options. Deudomperidone is designed to improve gastric emptying and alleviate symptoms of nausea and vomiting associated with gastroparesis. CinDome is actively enrolling patients for clinical trials targeting both idiopathic and diabetic gastroparesis.Explore more
Popular SearchesCindome Pharma IncCinDomeCindome PharmaSIC Code 87,873NAICS Code 54,541Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CinDome Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
CinDome Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CinDome Pharma had a recent Job posting/layoffs
Check out if CinDome Pharma is spiking on competitors!
Check if CinDome Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when CinDome Pharma launches new products
Earning: See what the market has to say on CinDome Pharma recently announced quarterly report
Funding: Get notified immidiatlly once CinDome Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at CinDome Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at CinDome Pharma
Find 3 more new buyers
Compare Similar Companies to CinDome Pharma
Compare insights from companies similar to CinDome Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CinDome Pharma
<$5M
11-50
Private
$59M
2019
N/A
Company Profile Activity
Activity Insights
CinDome Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CinDome Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CinDome Pharma.
CinDome Pharma financials insights
Gather financial insights about CinDome Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$59M
CinDome Pharma Tech Stack
A closer look at the technologies used by CinDome Pharma
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Event
Events
Event
CinDome Pharma News & Media
CinDome Pharma Announces $40 Million Series B Extension
CINCINNATI--(BUSINESS WIRE)--CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension. The additional funds from existing investors, including Perceptive Advisors and CinRx Pharma, bring the Series B raise total to $59 million. The capital will support the ongoing enrollment and evaluation of deudomperidone in the Phase 2 envision3D study in adults with diabetic gastroparesis and positiCinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
CINCINNATI--(BUSINESS WIRE)--CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis. The study presented at DDW assessed the effect of deudCinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
CINCINNATI--(BUSINESS WIRE)--CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois. The poster, titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study In Healthy Subjects” will highlight data on the promise of deudomperidone for the long-term management of gastroparesis. Gastroparesis impacts an estimated 16CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
CINCINNATI--(BUSINESS WIRE)--CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis. Deudomperidone is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being evaluated for the chronic treatment of patients who currently have no therapeutic options for lo
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CinDome Pharma
Sign Up For FreeTo access detailed company insights
CinDome Pharma, a CinRx portfolio company, is focused on developing deudomperidone (CIN-102) for the treatment of chronic gastroparesis, a condition affecting millions in the U.S. The company aims to provide a safe and effective long-term therapy for patients suffering from this debilitating condition, which currently lacks adequate treatment optio... Read More
